top of page

Eli Lilly's combination antibody therapy to fight COVID-19 has been granted by FDA

Lilly's combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%, data from a late-stage trial showed in January.

Lilly said the therapy will be available immediately.

Check out the full article right here.

bottom of page